Temas Destacados XXIV Congreso Nacional de ... - Gador SA

More documents

Recommendations

Info

52. North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high grade carotid stenosis. N Engl J Med 1991, 325:445–453. 53. Gaseeki AP, Eliaszio M, Ferguson GG, et al. Long term prognosis and effect of endarterectomy in patients with symptomatic severe carotid stenosis and contralateral stenosis or occlusion: results from North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. J Neurosurg 1995, 83:778–782. 54. Shawl FA. Carotid artery stenting: acute and longterm results. Current Opinion in Cardiology 2002, 17:671–676. 55. Agostoni E, Beghi E, Pappada G, et al. Early invasive treatment (endarterectomy vs. stenting) of moderateto-severe carotid stenosis in patients with transient ischaemic attack or minor stroke. Neurol Sci. 2005 May;26 Suppl 1:s31-3. 56. Wardlaw JM, Seymour J, Keir S, et al. Immediate Computed Tomography Scanning of Acute Stroke Is Cost-Effective and Improves Quality of Life. Stroke. 2004;35:2477. 57. Adams H, Adams R, Del Zoppo G, et al. Guidelines for the Early Management of Patients UIT Ischemic Stroke 2005 Guidelines Update A Scientific Statement From the Stroke Council of the American Heart Association/ American Stroke Association. Stroke. 2005;36:916-921. 58. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a metaanalysis of safety data. Stroke. 2003;34:2847–2850. 59. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557–563. 60. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346: 549–556. 61. Frohlich ED. Promise of prevention and reversal of target organ involvement in hypertension. J Renin Angiotensin Aldosterone Syst. 2001;2(Suppl 1):2–7. 62. Nixenberg A, Antony I. Epicardial coronary arteries are not adequately sized in hypertensive patients. J Am Coll Cardiol 1996;27:1115–1123. 63. Frohlich ED. Risk mechanisms in hypertensive heart disease. Hypertension 1999;34:782–789. - 17 - Highlight Gador de la FAC 64. Uribe Flores JD, Hernandez Jacome M, Guevara Donde J, et al. Losartan versus enalapril in the reduction of left ventricular hypertrophy secondary to systemic arterial hipertensión. Arch Cardiol Mex. 2004;74:192-9. 65. Deswal A, DeBakey M E. Diastolic dysfunction and diastolic heart failure: mechanisms and epidemiology. Curr Cardiol Rep 2005;7:178-83. 66. Mensah GA, Croft JB, Gile WH. The heart, kidney, and brain as target organs in hipertensión. Cardiol Clin 2002;20: 225–247. 67. Mulrow PJ. The intrarenal renin-angiotensin system. Curr Opin Nephrol Hypertens. 1993;2:41–44. 68. Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003; 31: 1213–20. 69. Pedrinelli R, Dell’Omo G, Di Bello V, et al. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002; 16: 79–89. 70. Ahmad J, Shafique S, Abidi SM, Parwez I. Effect of 5year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract. 2003;60:131-8. 71. Perico N, Ruggenenti P, Remuzzi G. Losartan in diabetic nephropathy. Expert Rev Cardiovasc Ther. 2004;2:473-83. 72. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921-7. 73. Safar ME, London GM. Therapeutic studies and arterial stiffness in hypertension: recommendations of the European Society of Hypertension. The Clinical Committee of Arterial Structure and Function. J Hypertens 2000; 18: 1527–1535. 74. Safar ME. Pulse pressure, arterial stiffness, and cardiovascular risk. Curr Opin Cardiol. 2000;15:258-63. 75. Sugawara J, Hayashi K, Yokoi T, et al. Brachial-ankle pulse wave velocity: an index of central arterial stiffness? J Hum Hypertens. 2005; 19:401-6. 76. Lim HS, Patel JV, Nadar S, et al. Comparison of brain natriuretic peptide and left ventricular diastolic function determined by tissue Doppler in patients with diabetes mellitus, patients with hypertension without diabetes, and in healthy subjects. Am J Cardiol. 2005;95:905-8.
Highlight Gador de la FAC 77. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25:39-42. 78. Viazzi F, Parodi D, Leoncini G, et al. Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005;45:991-6. 79. Zakopoulos NA, Tsivgoulis G, Barlas G, et al. Time rate of blood pressure variation is associated with increased common carotid artery intima-media thickness. Hypertension 2005;45:505-12. 80.Takiuchi S, Kamide K, Miwa Y, et al. Diagnostic value of carotid intima-media thickness and plaque score for predicting target organ damage in patients with essential hypertension. J Hum Hypertens. 2004;18:17- 23. 81. Swedberg K, Waagstein f, Hjalmarson A, Wallentin I: Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979; 30: 1374. 82. Epstein SE, Braunwald E:The effect of b-adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann Intern Med 1966;75:20 –27. 83. Packer M. Beta-Blockade in Heart Failure. Basic Concepts and Clinical Results. Am J Hypertens 1998;11:23S–37S. 84. Bristow MR, Hershberger RE, Port JD, et al: Betaadrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990;82(suppl D):12– 25. 85. Packer M. Current Role of Beta-Adrenergic Blockers in theManagement of Chronic Heart Failure. Am J Med. 2001;110(7A):81S–94S. 86. Ikeda U, Tsuruya Y, Yaginuma T: Alfa1-adrenergic stimulation is coupled to cardiac myocyte hypertrophy. Am J Physiol 1991;260:H953–H956. 87. Zimmer HG, Kolbeck-Ruhmkorff C, Zierhut W: Cardiac hypertrophy induced by alpha and b-adrenergic receptor stimulation. Cardioscience 1995;6:47–57. 88. Abraham WT, Tsvetkova T, Lowes BD, et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure [abstract]. Circulation. 1998;98(suppl I):378–379. 89. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225–1231. 90. Philip A Poole-Wilson, Karl Swedberg, John G F Cleland, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7–13. - 18 - 91. Fowler MB. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial: Carvedilol in Severe Heart Failure. Am J Cardiol 2004;93(suppl):35B–39B. 92. Colucci WS. Landmark Study: The Carvedilol Post- Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). Am J Cardiol 2004;93(suppl):13B–16B. 93. Sackner-Bernstein JD. Practical Guidelines to Optimize Effectiveness of beta-Blockade in Patients Postinfarction and in Those with Chronic Heart Failure. Am J Cardiol 2004;93(suppl):69B–73B. 94. Doris A, Ebmeier K, Shajahan P. Depressive illness. Lancet 1999; 354: 1369–75. 95. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349 (9063): 1436–42. 96. Shimbo D, Davidson KW, Haas DC, Fuster V, Badimon JJ. Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions. Journal of Thrombosis and Haemostasis 2005; 3: 897–908. 97. Laghrissi-thode F, Wagner WR, Pollock B, et al. Elevated platelet factor 4 and B-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997; 42: 290–5. 98. Shimbo D, Child J, Davidson K, et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 2002; 89: 331–3. 99. Chrapko WE, Jurasz P, Radomski MW, et al. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol. Psychiatry 2004; 56: 129–34. 100. DiMatteo MR, LepperHS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101–7. 101. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; 289: 3106–16. 102. Krishnan KR. Comorbidity and depression treatment. Biol Psychiatry 2003; 53: 701–6.
Page 2 and 3: Aspectos destacados del XXIV Congre
Page 4 and 5: Introducción El XXIV Congreso Naci
Page 6 and 7: Propiedades antioxidantes de las es
Page 8 and 9: Niacina más estatina. Otra combina
Page 10 and 11: a una disminución del estado proin
Page 12 and 13: Hipotermia. Dos artículos de los
Page 14 and 15: Beta bloqueantes en el tratamiento
Page 16 and 17: Estrés y depresión en cardiologí
Page 18 and 19: Referencias 1. Kannel WB, Castelli

Temas Destacados XXIV Congreso Nacional de ... - Gador SA

Create successful ePaper yourself

Delete template?

Save as template?